Turnage Richard H, Sarosi George, Cryer Byron, Spechler Stuart, Peterson Walter, Feldman Mark
Department of Surgery, Louisiana State University Health Science Center-Shreveport, Shreveport, LA 71130, USA.
J Gastrointest Surg. 2003 Jul-Aug;7(5):606-26. doi: 10.1016/s1091-255x(02)00034-3.
This systematic review examines the evidence for commonly employed strategies of managing patients with recurrent ulcer disease after acid-reducing operations. Particular attention is given to recent evidence relating Helicobacter pylori (H. pylori ) and nonsteroidal anti-inflammatory drugs (NSAIDs) to ulcer recurrence after operative therapy. MEDLINE word searches of the literature from 1966 to 2001 identified 895 articles that cross-reference the terms "peptic ulcer disease (PUD)," "surgery," and "recurrence." Articles were selected for systematic review of evidence relating incomplete vagotomy, NSAIDs, and H. pylori to postoperative ulcer recurrence and evidence supporting common medical and surgical strategies. The relationship between incomplete vagotomy and recurrent ulcer disease is suggested by randomized controlled trials and well-designed prospective case series. The evidence that NSAID use is an important pathogenic factor in recurrent ulcer disease includes the relationship between NSAIDs and primary PUD, the occurrence of NSAID-induced ulcers in patients taking proton pump inhibitors, and case series demonstrating virulent ulcer disease in patients taking aspirin despite prior acid-reducing operations. The relationship between H. pylori infection and postoperative ulcer recurrence remains uncertain despite multiple controlled trials and well-designed case series that have documented high rates of H. pylori infection in postoperative patients. The initial management of patients with recurrent ulcer disease after acid-reducing operations consists of a protein pump inhibitor or a histamine-2 receptor antagonist and antibiotics directed at H. pylori, if present. Evidence for this regimen includes prospective randomized trials demonstrating the efficacy of cimetidine in healing ulcers after acid-reducing operations and prospective, randomized studies documenting the efficacy of histamine-2 receptor antagonists and protein pump inhibitors in the management of patients with primary PUD. The critical role that H. pylori infection plays in primary PUD and the minimal risks associated with H. pylori eradication strongly support the initiation of antibiotic therapy when H. pylori is present. The principal indication for operative management of recurrent PUD is the occurrence of ulcer complications that cannot be managed by medical or endoscopic means. The operative management of patients with failed acid-reducing operations is based on ulcer recurrence rates and morbidity and mortality rates in randomized and nonrandomized prospective trials of patients with primary PUD and retrospective case series of patients undergoing remedial operative procedures after various failed acid-reducing operations.
本系统评价考察了用于治疗胃酸分泌减少手术后复发性溃疡病患者的常用策略的证据。特别关注了近期有关幽门螺杆菌(H. pylori)和非甾体抗炎药(NSAIDs)与手术治疗后溃疡复发之间关系的证据。对1966年至2001年的文献进行MEDLINE检索,共识别出895篇交叉引用“消化性溃疡病(PUD)”“手术”和“复发”等术语的文章。选取这些文章,对有关不完全迷走神经切断术、NSAIDs和H. pylori与术后溃疡复发关系的证据,以及支持常用内科和外科治疗策略的证据进行系统评价。随机对照试验和设计良好的前瞻性病例系列提示了不完全迷走神经切断术与复发性溃疡病之间的关系。NSAIDs使用是复发性溃疡病重要致病因素的证据包括:NSAIDs与原发性PUD的关系、服用质子泵抑制剂患者中NSAID诱导溃疡的发生,以及病例系列显示服用阿司匹林的患者尽管之前接受了胃酸分泌减少手术仍发生严重溃疡病。尽管多项对照试验和设计良好的病例系列记录了术后患者幽门螺杆菌感染率很高,但幽门螺杆菌感染与术后溃疡复发之间的关系仍不确定。胃酸分泌减少手术后复发性溃疡病患者的初始治疗包括使用质子泵抑制剂或组胺-2受体拮抗剂,如有幽门螺杆菌感染则使用针对该菌的抗生素。该治疗方案的证据包括前瞻性随机试验证明西咪替丁在胃酸分泌减少手术后愈合溃疡的疗效,以及前瞻性随机研究记录组胺-2受体拮抗剂和质子泵抑制剂在治疗原发性PUD患者中的疗效。幽门螺杆菌感染在原发性PUD中所起的关键作用以及根除幽门螺杆菌相关的最小风险,有力支持了存在幽门螺杆菌时开始抗生素治疗。复发性PUD手术治疗的主要指征是出现无法通过内科或内镜手段处理的溃疡并发症。胃酸分泌减少手术失败患者的手术治疗基于原发性PUD患者随机和非随机前瞻性试验以及各种胃酸分泌减少手术失败后接受补救性手术患者的回顾性病例系列中的溃疡复发率、发病率和死亡率。